All News

renal.genes_.jpg

Iberdomide in Systemic Lupus Erythematosus

d Jack Cush, MD

The NEJM reports that systemic lupus erythematosus (SLE) patients treated with iberdomide, a cereblon modulator, was effective at yielding a significant SRI-4 clinical response after 24 weeks. 

Read Article
Bronchiectasis_342x198_M1200048.jpg

Seropositivity Linked to Bronchiectasis in Rheumatoid Arthritis

d Jack Cush, MD

Rheumatoid arthritis associated bronchiectasis (RA-BR) is uncommon, and is unrelated to interstitial lung disease (ILD), but like ILD, can substantially impact RA outcomes.

Read Article
gout.toe_.MTP_.jpg

Disappointment Behind Acute Gout Hospitalizations

d Jack Cush, MD

Analysis of emergency department visits from two UK hospitals shows a high rate of hospitalization, and low use of urate-lowering therapies (ULT) and treat-to-target (T2T) management. 

Read Article
pollution,smoke

Environmental Pollutants Ups Autoimmune Disease Risk

d Jack Cush, MD

An Italian environmental study shows that air pollution increases the risk of autoimmune diseases, in particular rheumatoid arthritis, connective tissue diseases (CTDs) and inflammatory bowel diseases (IBD).

Read Article
SI AS SpA ACR

Individualized Therapy in Ankylosing Spondylitis

d MedPage Today

Whether patients with ankylosing spondylitis (AS) would improve substantially with tumor necrosis factor (TNF) inhibitor therapy was predicted with moderate to high accuracy based only on a standard lab test and two measures of disease activity, researchers reported from a modeling study.

Read Article
RA, hands, MCP, deformity

Low Dose IL-2 Efficacy in Rheumatoid Arthritis

d Jack Cush, MD

A novel biologic intervention trial has shown that subcutaneous, intermittent therapy with low-dose interleukin-2 (Ld-IL2) is potentially effective and safe in rheumatoid arthritis (RA).

Read Article
Another Rx for #PsA #psoriaticarthritis Deucravacitinib is shown to be effective. Good news but this adds to the dilemma of what to use in PsA Rx and in what order. Rational Rx may need #personalized Rx for best bang for buck! https://t.co/JQs7BlQwos

Links:

Janet Pope Janetbirdope ( View Tweet)

Individualized Therapy in Ankylosing Spondylitis Whether patients with AS would improve substantially with TNF inhibitor therapy was predicted with moderate to high accuracy based on a lab test and two measures of disease activity, researchers reported. https://t.co/hbbYqTiWGE https://t.co/Hx2U4y2e0F

Links:

Dr. John Cush RheumNow ( View Tweet)
Intravenous (IV) form of tramadol (Schedule IV) went in front of the FDA Drug Safety & Risk and Anesthetic/Analgesic Advisory Committees yesterday. They voted 14-8 against approval of IV tramadol (now available as tabs, liquid) https://t.co/AP2G7w8z1h https://t.co/lr9aLJSKi6

Links:

Dr. John Cush RheumNow ( View Tweet)
Low Dose IL-2 Efficacy in Rheumatoid Arthritis A novel biologic intervention trial has shown that subcutaneous, intermittent therapy with low-dose interleukin-2 (Ld-IL2) is potentially effective and safe in rheumatoid arthritis (RA). https://t.co/ycDgLT9EAA https://t.co/NJi48FZzAa

Links:

Dr. John Cush RheumNow ( View Tweet)
Metanalysis looked at the risk of psoriasis or PsA flare associated with steroid use. 11 retro- and prospective cohorts (4,170 820 pts) w/ 38% of PsA & 35% psoriasis Rx w/ systemic steroids. 10/11 studies did not show increased flares w/ steroids https://t.co/8o8hINFOrr https://t.co/85OYtWnGMJ

Links:

Dr. John Cush RheumNow ( View Tweet)
New download available on Methotrexate overview. https://t.co/dpyS4TS6tf https://t.co/2VsiqdX7WU

Links:

Dr. John Cush RheumNow ( View Tweet)
Who's to Blame? A Patient with Psoriatic Arthritis Dies from Sepsis - what was the cause of sepsis and death? QD Clinic is sponsored by https://t.co/4UQlqwujiR (March 19 & 20, 2022 in Las Colinas, Texas) https://t.co/lUfQHpNIOc https://t.co/HHk4hFs5ZS

Links:

Dr. John Cush RheumNow ( View Tweet)
Efficacy and Safety of Mavrilimumab in Giant Cell Arteritis A phase II trial in patients with active giant cell arteritis shows that mavrilimumab, a monoclonal antibody against GM-CSF is capable of inducing clinical remission. https://t.co/QmACP1ESFG https://t.co/EeWxTZuFbw

Links:

Dr. John Cush RheumNow ( View Tweet)
Doctors in the Dark The modern way to real-time consult with specialists QD Clinic is sponsored by https://t.co/4UQlqwujiR (March 19 & 20, 2022 in Las Colinas, Texas) https://t.co/rd5blbrORD https://t.co/O5X64tKNmh

Links:

Dr. John Cush RheumNow ( View Tweet)
Predicting Spondylitis in At-Risk Relatives The risk of developing axSpA if you’re a first-degree relative (FDRs) of an AS patient has been defined by a 35 year follow-up study showing that if you are a FDR of axSpA you may be at higher risk of AAU. https://t.co/wezFZUhyZZ https://t.co/VASbJZt9UV

Links:

Dr. John Cush RheumNow ( View Tweet)
Join us on Saturday either in-person or virtually! https://t.co/GY4ZPderis https://t.co/OIo5QHBqEF

Links:

Dr. John Cush RheumNow ( View Tweet)

Study of 1141 consecutive gouty pts finds 10 (0.9%) with "Shrinking Toes" in those w/ tophaceous gout (usually MTP1,2) - toe shortening mainly due to lytic bone collapse during articular tophus dissolution (esp in severe gout w/ severe erosions) https://t.co/fiwhiDKKgf https://t.co/C22GpGiA1l

Links:

Dr. John Cush RheumNow ( View Tweet)
In a Belgian cohort study of 2492 RA pts, 697 Rx w/ a TNF inhibitor -- four developed TNFi (3ETN, 1INFLX) induced sarcoidosis. 2 w/ pulm sarcoid and hilar LN; 1 Heerfordt synd; 1 w/ granulomas and ^^calcium. All recoved w/ steroids and TNFi-DC https://t.co/qvUND1WER4 https://t.co/wxN2SYjcIn

Links:

Dr. John Cush RheumNow ( View Tweet)
What happens in the UK and Europe doesn't stay there. 5 out of 5 warnings predicted what would happen in this US. Let's make believe the 6th won't. https://t.co/BFPpGsZXV7
Eric Topol EricTopol ( View Tweet)
×